Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline

Hypogonadism: full-pipeline trial registry

5 of 22 indexed Hypogonadism trials are currently recruiting.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 5 currently recruiting · #756 of 28,707 conditions by registered trial count

Hypogonadism: 22 US clinical trials tracked, 5 recruiting.

Hypogonadism is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Environmental Health Sciences (NIEHS), running 2 of these trials.

Enrollment posture brief

Registry condition hypogonadism

OPEN 5 | RECR 23% | LATE 7 | EARLY 9 | RANK #756 | SPON 2

Nearest open-share peer: Migraine Disorders (23% recruiting · 22 trials)

Advanced Melanoma63.6%Hypogonadism (this)23%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Hypogonadism

Hypogonadism lists 5 open slots (23% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypogonadism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypogonadism is recruiting below its size-band peers.

    5 of 22 indexed trials (22.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hypogonadism trials is spread across many organizations.

    National Institute of Environmental Health Sciences (NIEHS) accounts for 2 of 22 trials (9.1%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Most Hypogonadism trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 22 trials that report a genuine target (sentinel values excluded). 16 of those (72.7%) plan for fewer than 100 participants.

  4. Hypogonadism research is mostly interventional.

    17 interventional and 5 observational studies make up this index (77.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 26Phase 31Phase 46

Open and recent trials

22 total, page 1 of 1

RECRUITING 850 participants

Inherited Reproductive Disorders

National Institute of Environmental Health Sciences (NIEHS)

NCT01500447

RECRUITING 300 participants

Observation of Environment and Reproductive-Endocrine Effects

National Institute of Environmental Health Sciences (NIEHS)

NCT06280807

RECRUITING Phase 4 120 participants

Adaptions and Resiliency to Multi-Stressor OpeRations

Bradley Nindl

NCT06455969

RECRUITING 75 participants

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

Walter Reed National Military Medical Center

NCT06247267

RECRUITING Phase 2 21 participants

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

North Florida Foundation for Research and Education

NCT04460872

ACTIVE NOT RECRUITING Phase 4 110 participants

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Tolmar

NCT06385509

ACTIVE NOT RECRUITING Phase 4 92 participants

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

VA Office of Research and Development

NCT03887936

ACTIVE NOT RECRUITING Phase 1 56 participants

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Emory University

NCT04731376

COMPLETED Phase 4 308 participants

Testosterone Replacement in Older Men and Atherosclerosis Progression

Brigham and Women's Hospital

NCT00287586

COMPLETED Phase 2 100 participants

A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism

QuatRx Pharmaceuticals Company

NCT00290134

COMPLETED Phase 4 78 participants

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

Eli Lilly and Company

NCT01893281

COMPLETED Phase 3 75 participants

Testopel ® vs. Generic Testosterone Pellets.

University of Miami

NCT04523480

COMPLETED 70 participants

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

National Institute of Mental Health (NIMH)

NCT00001412

COMPLETED Phase 2 43 participants

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

GlaxoSmithKline

NCT00398580

COMPLETED Phase 2 40 participants

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

Watson Pharmaceuticals

NCT01323140

COMPLETED NA 40 participants

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00470990

COMPLETED Phase 2 35 participants

Testosterone and Growth Hormone for Bone Loss in Men

University of Pennsylvania

NCT00080483

COMPLETED 30 participants

Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR

Lamm, Steven, M.D.

NCT00425568

COMPLETED Phase 1 24 participants

Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

Solvay Pharmaceuticals

NCT00998933

COMPLETED Phase 4 24 participants

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

The Miriam Hospital

NCT00752869

COMPLETED Phase 2 18 participants

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

Clarus Therapeutics

NCT02921386

COMPLETED Phase 1 16 participants

ORAL T-6: Oral Androgens in Man-6

University of Washington

NCT00663793

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 1
Phase 4 6

Named interventions

Most-linked intervention names on Hypogonadism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Testosterone gel 1.62% Drug
2 trials
Placebo Drug
2 trials
AndroGel (Transdermal Testosterone Gel) Drug
1 trials
Oral Testosterone Undecanoate Drug
1 trials
Testopel 200mg Drug Implant Drug
1 trials
Testopel 100mg Drug Implant Drug
1 trials
Testopel 75mg Drug Implant Drug
1 trials
commercially available dutasteride Drug
1 trials

US sites by state

Facility locations filed on Hypogonadism trials. A trial with sites in several states counts in each.

Florida 7 trials
Maryland 6 trials
California 6 trials
Texas 5 trials
North Carolina 5 trials
Washington 4 trials
New York 4 trials
Massachusetts 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hypogonadism page

22 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypogonadism condition card totals 22 registered trials; most-linked intervention Testosterone gel 1.62%; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.